+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

SPECT - Global Market Trajectory & Analytics

  • ID: 5140130
  • Report
  • September 2020
  • Region: Global
  • 230 pages
  • Global Industry Analysts, Inc
Global Single Photon Emission Computed Tomography (SPECT) Market to Reach $1.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Cardiology, one of the segments analyzed in the report, is projected to record a 5.6% CAGR and reach US$762.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Oncology segment is readjusted to a revised 5.1% CAGR for the next 7-year period.



The U. S. Market is Estimated at $390.2 Million, While China is Forecast to Grow at 4.5% CAGR

The Single Photon Emission Computed Tomography (SPECT) market in the U. S. is estimated at US$390.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$324.4 Million by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

General Imaging Segment to Record 3.5% CAGR

In the global General Imaging segment, USA, Canada, Japan, China and Europe will drive the 3.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$270.3 Million in the year 2020 will reach a projected size of US$346.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$204.3 Million by the year 2027. We bring years of research experience to this 6th edition of our report. The 230-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:
  • Bruker Corporation
  • Digirad Corporation
  • Esaote SpA
  • GE Healthcare
  • Invicro, LLC
  • Mediso Medical Imaging Systems
  • MR Solutions Ltd.
  • Philips Healthcare
  • Siemens Healthineers
  • Trifoil Imaging, Inc.
Note: Product cover images may vary from those shown
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Impact of Covid-19 and a Looming Global Recession
  • Global Competitor Market Shares
  • Single Photon Emission Computed Tomography (SPECT) Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Current & Future Analysis for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 2: World Historic Review for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 3: World 15-Year Perspective for SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • TABLE 4: World Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 5: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 6: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 7: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 8: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 9: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 10: World Current & Future Analysis for General Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 11: World Historic Review for General Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 12: World 15-Year Perspective for General Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 13: World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 14: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 15: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 16: World Current & Future Analysis for Standalone SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 17: World Historic Review for Standalone SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 18: World 15-Year Perspective for Standalone SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 19: World Current & Future Analysis for Hybrid SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 20: World Historic Review for Hybrid SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 21: World 15-Year Perspective for Hybrid SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 22: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 24: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 25: World Current & Future Analysis for Diagnostic Centers and Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 26: World Historic Review for Diagnostic Centers and Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 27: World 15-Year Perspective for Diagnostic Centers and Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • TABLE 28: World Current & Future Analysis for Academic and Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 29: World Historic Review for Academic and Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 30: World 15-Year Perspective for Academic and Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
  • Market Facts & Figures
  • US SPECT Market Share (in %) by Company: 2019 & 2025
  • Market Analytics
  • TABLE 31: USA Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 32: USA Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 33: USA 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 34: USA Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 35: USA Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 36: USA 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 37: USA Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 38: USA Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 39: USA 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
CANADA
  • TABLE 40: Canada Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 41: Canada Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 42: Canada 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 43: Canada Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 44: Canada Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 45: Canada 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 46: Canada Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 47: Canada Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 48: Canada 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
JAPAN
  • TABLE 49: Japan Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 50: Japan Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 51: Japan 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 52: Japan Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 53: Japan Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 54: Japan 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 55: Japan Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 56: Japan Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 57: Japan 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
CHINA
  • TABLE 58: China Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 59: China Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 60: China 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 61: China Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 62: China Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 63: China 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 64: China Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 65: China Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 66: China 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
EUROPE
  • Market Facts & Figures
  • European SPECT Market: Competitor Market Share Scenario (in %) for 2019 & 2025
  • Market Analytics
  • TABLE 67: Europe Current & Future Analysis for SPECT by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027
  • TABLE 68: Europe Historic Review for SPECT by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 69: Europe 15-Year Perspective for SPECT by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • TABLE 70: Europe Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 71: Europe Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 72: Europe 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 73: Europe Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 74: Europe Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 75: Europe 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 76: Europe Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 77: Europe Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 78: Europe 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
FRANCE
  • TABLE 79: France Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 80: France Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 81: France 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 82: France Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 83: France Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 84: France 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 85: France Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 86: France Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 87: France 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
GERMANY
  • TABLE 88: Germany Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 89: Germany Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 90: Germany 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 91: Germany Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 92: Germany Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 93: Germany 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 94: Germany Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 95: Germany Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 96: Germany 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
ITALY
  • TABLE 97: Italy Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 98: Italy Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 99: Italy 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 100: Italy Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 101: Italy Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 102: Italy 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 103: Italy Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 104: Italy Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 105: Italy 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
UNITED KINGDOM
  • TABLE 106: UK Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 107: UK Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 108: UK 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 109: UK Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 110: UK Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 111: UK 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 112: UK Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 113: UK Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 114: UK 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
REST OF EUROPE
  • TABLE 115: Rest of Europe Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 116: Rest of Europe Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 117: Rest of Europe 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 118: Rest of Europe Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 119: Rest of Europe Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 120: Rest of Europe 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 121: Rest of Europe Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 122: Rest of Europe Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 123: Rest of Europe 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
ASIA-PACIFIC
  • TABLE 124: Asia-Pacific Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 125: Asia-Pacific Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 126: Asia-Pacific 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 127: Asia-Pacific Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 128: Asia-Pacific Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 129: Asia-Pacific 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 130: Asia-Pacific Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 131: Asia-Pacific Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 132: Asia-Pacific 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
REST OF WORLD
  • TABLE 133: Rest of World Current & Future Analysis for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 134: Rest of World Historic Review for SPECT by Application - Cardiology, Oncology, General Imaging and Neurology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 135: Rest of World 15-Year Perspective for SPECT by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, General Imaging and Neurology for the Years 2012, 2020 & 2027
  • TABLE 136: Rest of World Current & Future Analysis for SPECT by Product Type - Standalone SPECT and Hybrid SPECT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 137: Rest of World Historic Review for SPECT by Product Type - Standalone SPECT and Hybrid SPECT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 138: Rest of World 15-Year Perspective for SPECT by Product Type - Percentage Breakdown of Value Sales for Standalone SPECT and Hybrid SPECT for the Years 2012, 2020 & 2027
  • TABLE 139: Rest of World Current & Future Analysis for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027
  • TABLE 140: Rest of World Historic Review for SPECT by End-Use - Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019
  • TABLE 141: Rest of World 15-Year Perspective for SPECT by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Clinics and Academic and Research Centers for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll